Immuneering Announces Inclusion in the Russell 2000® Index
September 20 2021 - 4:10PM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
advancing a robust pipeline of oncology and neuroscience product
candidates that are designed to uniquely disrupt cellular signaling
dynamics, today announced that Immuneering Corporation has been
selected to be added to the Russell 2000® Index effective
September 20, 2021, after the close of the U.S. equity markets.
“We are pleased to have been selected for inclusion in the
Russell 2000® Index. Our placement in this widely used
performance benchmark for small-cap companies reflects the success
of our recent Initial Public Offering and our progress toward drugs
targeting cancers driven by alterations that activate the RAS/MAPK
pathway. With our inclusion in the Russell 2000®, we look forward
to increased exposure to the investment community and other key
stakeholders with our story,” said Ben Zeskind, Ph.D., Co-Founder,
President and Chief Executive Officer of Immuneering.
The Russell 2000® Index measures the performance of the
small-cap segment of the US equity market. The Russell
2000® Index is a subset of the Russell 3000® Index
representing approximately 10% of the total market capitalization
of that index. It includes approximately 2,000 of the smallest
securities based on a combination of their market cap and current
index membership.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets
are benchmarked against Russell’s U.S. indexes which are part of
FTSE Russell, a global index leader that provides innovative
benchmarking, analytics and data solutions for investors
worldwide.
For more information on the Russell Indexes, please visit the
FTS Russell website at www.ftserussell.com.
About Immuneering
Corporation Immuneering
is a biopharmaceutical company with an emerging pipeline focused on
improving patient outcomes across a spectrum of debilitating
oncologic and neurologic diseases by applying its deep knowledge of
translational bioinformatics to every stage of the drug development
process. Immuneering has more than a decade of experience in
translational bioinformatics and generating insights into drug
mechanisms of action and patient treatment responses. Building on
this experience, Immuneering has developed a disease-agnostic
platform that enables the company to utilize human data, novel
biology and chemistry, and translational planning to create and
advance its wholly owned pipeline. Immuneering’s current
development programs in oncology are focused on providing potential
treatments for patients with solid tumors caused by mutations of
oncologic signaling pathways, including the MAPK pathway.
Immuneering’s lead product candidate, IMM-1-104, is designed to be
a highly selective dual-MEK inhibitor that further disrupts KSR for
the treatment of advanced solid tumors in patients harboring RAS
mutant tumors. Additionally, Immuneering has six other oncology
programs in the discovery stage that are designed to target either
the MAPK or mTOR pathway, and two neuroscience programs in the
discovery
stage.
Forward-Looking Statements
This press release includes certain disclosures that contain
"forward-looking statements," including, without limitation,
statements regarding Immuneering’s progress toward drugs targeting
cancers driven by alterations that activate the RAS/MAPK pathway
and the increased market exposure from being included in the
Russell 2000® Index. Forward-looking statements are based on
Immuneering’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, the risks inherent in oncology and neuroscience
drug development, including target discovery, target validation,
lead compound identification, lead compound optimization,
preclinical studies and clinical trials. These and other risks and
uncertainties are described more fully in the section titled "Risk
Factors" in the Company’s most recent Form 10-Q filed with the U.S.
Securities and Exchange Commission (SEC) as well as in
Immuneering’s subsequent filings it makes with the SEC.
Forward-looking statements contained in this announcement are made
as of this date, and Immuneering undertakes no duty to update such
information except as required under applicable law.
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering
Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Anne Marie FieldsManaging
DirectorRx Communicationsafields@rxir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024